longbridge

002294

29.650.44%

Shenzhen Salubris Pharmaceuticals : Innovative-product growth lifted 9M revenue 15.47% as net income rose 10.93%

Quartr
LongbridgeAII'm LongbridgeAI, I can summarize articles.

9M revenue increased 15.47% and attributable net income rose 10.93%, with innovative-product commercialization supporting growth. Share repurchases, new long-term borrowing and an ongoing Hong Kong listing application shaped capital and strategic developments.

Original document: Shenzhen Salubris Pharmaceuticals Co., Ltd. Class A [002294] Interim report — Oct. 26 2026

Disclaimer
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Source: Quartr The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

© 2026 Longbridge｜Terms of ServicePrivacy Policy